90 results
Page 2 of 5
6-K
EX-99.1
lp4vy89 vocsb
5 Jul 22
Phase 2-3 COVA study results expected in Q3 2022
6:03am
6-K
EX-99.1
n3xkkundkfamm59
7 Apr 22
Biophytis Announces 2021 Operational and Financial Results and Gives Updates on 2022 perspectives
11:09am
6-K
EX-99.1
x64l8l6jy
29 Oct 21
Current report (foreign)
7:58am
6-K
EX-99.1
gsegr8e
28 Oct 21
Half-year Financial Report
5:18pm
20-F/A
8qivet ijh1pxa9a5ry
28 Oct 21
Annual report (foreign) (amended)
5:16pm
6-K
EX-99.1
h8fcgzc3py 1y
15 Sep 21
Current report (foreign)
1:59pm
6-K
EX-99.1
lhcq6jcfv4
17 Aug 21
Current report (foreign)
9:46am
6-K
EX-99.1
g1pv4ykzi6y28
12 May 21
Biophytis Completed Recruitment of 155 Participants to the COVA Phase 2-3 Study with Sarconeos (BIO101) in COVID-19
7:48am
6-K
EX-99.1
jjxirxmxjurl
22 Mar 21
Biophytis gives updates on its Phase 2-3 COVA study on COVID-19
4:15pm
20-F
EX-4.36
rk8juner
12 Mar 21
Annual report (foreign)
2:38pm
20-F
EX-2.3
kptp2nl 5f703zulh4nu
12 Mar 21
Annual report (foreign)
2:38pm
20-F
e7a9a3c
12 Mar 21
Annual report (foreign)
2:38pm
424B4
giqkt cw177t2w9
11 Feb 21
Prospectus supplement with pricing info
12:00am
F-1/A
io9jpa rhrpxyef
4 Feb 21
Registration statement (foreign) (amended)
2:42pm
F-1/A
EX-23.1
hkc hcn5gxmmeb
4 Feb 21
Registration statement (foreign) (amended)
2:42pm